FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2480642725> ?p ?o ?g. }

• W2480642725 endingPage "1706" @default.
• W2480642725 startingPage "1697" @default.
• W2480642725 abstract "Loss of p53 suppressor function, through mutations or inactivation of the p53 pathway, occurs in most human cancers. SGT-53 is a liposomal nanocomplex designed for systemic, tumor-targeting delivery of the wt p53 gene. In this nanodelivery system, an anti-transferrin receptor single-chain antibody fragment serves as the targeting moiety. In an initial phase 1 trial in patients with advanced solid tumors, SGT-53 demonstrated tumor-specific targeting, was shown to be well tolerated, and was associated with an antitumor effect in several patients. Our preclinical studies have also demonstrated enhanced antitumor activity with the combination of SGT-53 and docetaxel. Thus, this dose-escalation trial was undertaken to assess the combination of SGT-53 and docetaxel for safety and potential efficacy in 14 advanced cancer patients. Results reveal that the combination of SGT-53 (maximum dose, 3.6 mg DNA/infusion) and docetaxel (75 mg/m2/infusion) was well tolerated. Moreover, clinical activity involving 12 evaluable patients was observed. Three of these patients achieved RECIST-verified partial responses with tumor reductions of −47%, −51%, and −79%. Two others had stable disease with significant shrinkage (−25% and −16%). These results support phase 2 testing of SGT-53 in combination with docetaxel. Loss of p53 suppressor function, through mutations or inactivation of the p53 pathway, occurs in most human cancers. SGT-53 is a liposomal nanocomplex designed for systemic, tumor-targeting delivery of the wt p53 gene. In this nanodelivery system, an anti-transferrin receptor single-chain antibody fragment serves as the targeting moiety. In an initial phase 1 trial in patients with advanced solid tumors, SGT-53 demonstrated tumor-specific targeting, was shown to be well tolerated, and was associated with an antitumor effect in several patients. Our preclinical studies have also demonstrated enhanced antitumor activity with the combination of SGT-53 and docetaxel. Thus, this dose-escalation trial was undertaken to assess the combination of SGT-53 and docetaxel for safety and potential efficacy in 14 advanced cancer patients. Results reveal that the combination of SGT-53 (maximum dose, 3.6 mg DNA/infusion) and docetaxel (75 mg/m2/infusion) was well tolerated. Moreover, clinical activity involving 12 evaluable patients was observed. Three of these patients achieved RECIST-verified partial responses with tumor reductions of −47%, −51%, and −79%. Two others had stable disease with significant shrinkage (−25% and −16%). These results support phase 2 testing of SGT-53 in combination with docetaxel." @default.
• W2480642725 created "2016-08-23" @default.
• W2480642725 creator A5002799252 @default.
• W2480642725 creator A5039264253 @default.
• W2480642725 creator A5053441593 @default.
• W2480642725 creator A5055054082 @default.
• W2480642725 creator A5058823658 @default.
• W2480642725 creator A5067935073 @default.
• W2480642725 date "2016-09-01" @default.
• W2480642725 modified "2023-10-10" @default.
• W2480642725 title "Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study" @default.
• W2480642725 cites W112828355 @default.
• W2480642725 cites W1537583887 @default.
• W2480642725 cites W1600706591 @default.
• W2480642725 cites W1835280798 @default.
• W2480642725 cites W1926267001 @default.
• W2480642725 cites W1950719160 @default.
• W2480642725 cites W1966743152 @default.
• W2480642725 cites W1973478663 @default.
• W2480642725 cites W1974692537 @default.
• W2480642725 cites W1975203744 @default.
• W2480642725 cites W1977506341 @default.
• W2480642725 cites W1978103469 @default.
• W2480642725 cites W1992708996 @default.
• W2480642725 cites W1996487606 @default.
• W2480642725 cites W1998775946 @default.
• W2480642725 cites W2004273407 @default.
• W2480642725 cites W2011189845 @default.
• W2480642725 cites W2022495797 @default.
• W2480642725 cites W2023568521 @default.
• W2480642725 cites W2027437657 @default.
• W2480642725 cites W2028387032 @default.
• W2480642725 cites W2029079706 @default.
• W2480642725 cites W2033791403 @default.
• W2480642725 cites W2040881358 @default.
• W2480642725 cites W2049247975 @default.
• W2480642725 cites W2051548025 @default.
• W2480642725 cites W2055349083 @default.
• W2480642725 cites W2058548073 @default.
• W2480642725 cites W2059999514 @default.
• W2480642725 cites W2061165346 @default.
• W2480642725 cites W2062457956 @default.
• W2480642725 cites W2064508063 @default.
• W2480642725 cites W2074114480 @default.
• W2480642725 cites W2078363421 @default.
• W2480642725 cites W2080323656 @default.
• W2480642725 cites W2081894694 @default.
• W2480642725 cites W2092878705 @default.
• W2480642725 cites W2103553318 @default.
• W2480642725 cites W2125540724 @default.
• W2480642725 cites W2133959309 @default.
• W2480642725 cites W2138422753 @default.
• W2480642725 cites W2139248078 @default.
• W2480642725 cites W2142058281 @default.
• W2480642725 cites W2144694610 @default.
• W2480642725 cites W2145732179 @default.
• W2480642725 cites W2150097377 @default.
• W2480642725 cites W2152584529 @default.
• W2480642725 cites W2154799239 @default.
• W2480642725 cites W2157472182 @default.
• W2480642725 cites W2159189771 @default.
• W2480642725 cites W2160178368 @default.
• W2480642725 cites W2163750567 @default.
• W2480642725 cites W2164380696 @default.
• W2480642725 cites W2169964349 @default.
• W2480642725 cites W2170204650 @default.
• W2480642725 cites W2171395653 @default.
• W2480642725 cites W2323860656 @default.
• W2480642725 cites W2332433189 @default.
• W2480642725 cites W2417740774 @default.
• W2480642725 cites W4253192850 @default.
• W2480642725 cites W74998615 @default.
• W2480642725 doi "https://doi.org/10.1038/mt.2016.135" @default.
• W2480642725 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5113104" @default.
• W2480642725 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27357628" @default.
• W2480642725 hasPublicationYear "2016" @default.
• W2480642725 type Work @default.
• W2480642725 sameAs 2480642725 @default.
• W2480642725 citedByCount "77" @default.
• W2480642725 countsByYear W24806427252016 @default.
• W2480642725 countsByYear W24806427252017 @default.
• W2480642725 countsByYear W24806427252018 @default.
• W2480642725 countsByYear W24806427252019 @default.
• W2480642725 countsByYear W24806427252020 @default.
• W2480642725 countsByYear W24806427252021 @default.
• W2480642725 countsByYear W24806427252022 @default.
• W2480642725 countsByYear W24806427252023 @default.
• W2480642725 crossrefType "journal-article" @default.
• W2480642725 hasAuthorship W2480642725A5002799252 @default.
• W2480642725 hasAuthorship W2480642725A5039264253 @default.
• W2480642725 hasAuthorship W2480642725A5053441593 @default.
• W2480642725 hasAuthorship W2480642725A5055054082 @default.
• W2480642725 hasAuthorship W2480642725A5058823658 @default.
• W2480642725 hasAuthorship W2480642725A5067935073 @default.
• W2480642725 hasBestOaLocation W24806427251 @default.
• W2480642725 hasConcept C121608353 @default.
• W2480642725 hasConcept C126322002 @default.
• W2480642725 hasConcept C22814914 @default.

• next